ShangBay Capital

Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Inquis Medical is focused on developing innovative thrombectomy technology aimed at enhancing the management of venous thromboembolic diseases. The company's medical devices are designed to address unmet clinical needs while improving the standard of care in this area. Inquis Medical's key offering is an efficient single-pass thrombectomy system that minimizes blood loss, contributing to better patient outcomes. Through its advanced technology, Inquis Medical seeks to provide solutions that have a lasting impact on the treatment of thromboembolic conditions.

Venova Medical specializes in developing vascular access systems aimed at improving the experience of patients requiring renal replacement therapy, particularly those needing hemodialysis. Founded in 2018 and based in Los Gatos, California, the company focuses on overcoming challenges related to vascular access creation. By addressing both patient-level and systemic barriers, Venova Medical provides solutions that facilitate quicker functioning access with reduced need for intervention. This approach not only enhances vascular access outcomes but also aims to lower associated costs, ultimately simplifying the process for patients in need of hemodialysis.

Avation Medical, Inc. is focused on developing a non-invasive closed-loop neuromodulation system designed for the at-home treatment of overactive bladder. Established in 2016 and based in Columbus, Ohio, the company is pioneering wearable nerve stimulation platforms that emphasize patient empowerment and personalized care. By re-imagining neuromodulation through innovative, proven technologies, Avation Medical aims to enhance the management of chronic conditions, offering solutions that prioritize the needs and experiences of patients.

Laplace Interventional is a medical device company focused on developing transcatheter tricuspid valve technology aimed at treating tricuspid regurgitation. The company's innovative prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. This approach not only enhances patients' life expectancy but also significantly improves their quality of life by reducing the risk of future complications. Through its advancements in cardiac care, Laplace Interventional is dedicated to providing effective solutions for patients worldwide.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, that focuses on developing a neuromodulation technology platform aimed at treating chronic pain and other disorders affecting neuronal activity. Founded in 2017, the company is dedicated to creating a new class of therapeutic medical devices through its innovative bioelectronic medicine. This platform is designed to provide patients with effective remedies for conditions related to neural activity, positioning Presidio Medical at the forefront of advancements in medtech and bioengineering.

Solenic Medical, Inc. is a medical device company founded in 2019 and based in College Station, Texas. It specializes in developing a non-invasive treatment for infected metallic implants using a technology that employs alternating magnetic fields generated by external coils. This innovative approach targets biofilm on the surfaces of medical implants, which is a significant complication in surgeries like knee and hip replacements, as well as in trauma-related procedures involving plates and rods. The technology has the potential to replace the costly and risky two-step revision surgical procedure currently used to address chronic infections in medical implants, thereby offering a safer and more effective solution for patients.

Noah Medical is a manufacturer of medical robotic devices aimed at enhancing the diagnosis and treatment of patients in various healthcare settings. The company's innovative devices facilitate early diagnoses and treatments, particularly in advanced clinical environments. By enabling hospitals to address medical issues promptly, Noah Medical's technology contributes to improved patient outcomes and minimizes scarring associated with procedures.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company aims to identify 'switch sites,' which are druggable regions crucial for regulating transcription factors, to target mutations associated with various diseases. Flare's innovative approach has advanced its drug discovery efforts, resulting in a promising pipeline of programs that primarily address well-established transcription factors. Initially concentrating on precision oncology, the company's research also holds potential applications in neurology, rare genetic disorders, immunology, and inflammation. By leveraging insights from its scientific founders, Flare Therapeutics seeks to transform the treatment landscape for cancer patients and other disease areas.

Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Telesair is a medical device company focused on developing innovative respiratory care solutions aimed at enhancing the quality of life for individuals with lung diseases. By leveraging real clinical data, engineering design, software, and Internet of Things (IoT) technology, Telesair creates respiratory care equipment that is both safer and more efficient. Their products are designed for use in clinical settings and at home, facilitating a transition for patients from hospital care to home care more swiftly. This approach not only improves patient outcomes but also optimizes the standard of care in respiratory health management.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing male birth control solutions. The company is creating an innovative, long-lasting, non-hormonal, and reversible contraceptive known as Echo-V. This product consists of an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device acts as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and user-friendly approach to male contraception. Founded in 2015, Contraline aims to transform male reproductive health through its groundbreaking technology.

Huma.AI, Inc. is a technology company based in Palo Alto, California, that focuses on developing a knowledge automation platform designed to enhance efficiency in the healthcare and pharmaceutical industries. Founded in 2016, the company addresses the challenges posed by disparate systems and the vast amounts of unstructured data that complicate decision-making. By serving as a connector between data silos, Huma.AI enables users to access insights and actionable information through natural language queries. The platform is capable of extracting valuable insights from various document formats, allowing companies, scientists, and clinicians to make informed decisions quickly and effectively. Through this innovative approach, Huma.AI aims to streamline healthcare processes and improve overall operational efficiency.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing male birth control solutions. The company is creating an innovative, long-lasting, non-hormonal, and reversible contraceptive known as Echo-V. This product consists of an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device acts as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and user-friendly approach to male contraception. Founded in 2015, Contraline aims to transform male reproductive health through its groundbreaking technology.

Laplace Interventional is a medical device company focused on developing transcatheter tricuspid valve technology aimed at treating tricuspid regurgitation. The company's innovative prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. This approach not only enhances patients' life expectancy but also significantly improves their quality of life by reducing the risk of future complications. Through its advancements in cardiac care, Laplace Interventional is dedicated to providing effective solutions for patients worldwide.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Neuro42 is focused on developing and commercializing advanced magnetic resonance imaging (MRI) and robotics technology aimed at diagnosing and guiding interventions for neurological conditions. The company has created portable MRI machines designed to enhance the diagnostic process for various brain issues, including traumatic injuries, epilepsy, and tumors. By providing imaging solutions that facilitate triaging, screening, and direct robotic interventions, Neuro42 aims to improve patient care, particularly for those who have suffered strokes. This innovative approach shifts the point of care from traditional MRI suites to more accessible settings, enabling timely and effective treatment for neurological conditions.

Emboline, Inc. is a medical device company specializing in the development of cardiovascular embolic protection devices for various cardiac procedures. The company has created innovative technologies such as the Emboline Complete Accessible Protection and the Emboliner catheter, which are designed to protect the arterial bed and cerebral arteries, respectively. These devices are particularly useful during percutaneous heart valve repair and replacement procedures, as they mitigate the risk of embolic events that can impact critical organs. Founded in 2011 and headquartered in Santa Cruz, California, Emboline serves diverse markets, including cardiac surgery, cardiopulmonary bypass, interventional cardiology, and interventional electrophysiology. As of early 2013, Emboline operates as a subsidiary of CardioLogical Solutions.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Aqua Medical, Inc. is focused on developing innovative, vapor-based, endoscopic ablation technology aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 and based in Santa Ana, California, the company utilizes high-temperature water vapor generated by a radiofrequency generator. This vapor is delivered endoscopically through proprietary catheters, allowing for a minimally invasive approach to treat various conditions within the gastrointestinal tract, including pancreatic cysts and esophageal issues. Aqua Medical's platform technology offers a convenient and effective alternative to traditional surgical methods, enhancing treatment options for medical practitioners and their patients.

OrthoFX, LLC is a technology company based in Fremont, California, that specializes in online clear aligner solutions for dental straightening. Founded in 2018, the company offers a comprehensive platform designed for orthodontists and general dentists, enhancing the treatment experience for both practitioners and patients. OrthoFX's services include full treatment plans, smile evolution treatments, and online braces, supported by advanced technologies such as virtual treatment coordinators and AI-powered remote monitoring. Their platform also features wear-time tracking through sensors and proprietary polymers, which aim to streamline the orthodontic process and reduce the need for treatment reboots. Additionally, OrthoFX provides insurance concierge services and integrated financing options to further support dental professionals and improve patient satisfaction.

Zeto Inc. is a medical technology company based in Santa Clara, California, focused on revolutionizing electroencephalography (EEG) practices in hospitals. Established in 2014, Zeto has developed an innovative dry electrode EEG system that features a wireless, easy-to-wear headset designed to enhance patient experience and streamline the EEG process. This system is the first of its kind to receive FDA clearance, eliminating the need for extensive preparation and specialized technicians. It significantly reduces setup time from over 30 minutes to just five, allowing for quicker and more efficient EEG interpretation. The accompanying digital platform offers instant data upload, live viewing capabilities, and analytical tools, enabling remote analysis by neurologists. Zeto has gained recognition for its advancements in EEG technology, receiving multiple awards, including funding from the Epilepsy Foundation and accolades for innovation in medical technology.

Zap Surgical Systems, Inc. is a medical technology company based in San Carlos, California, founded in 2014. The company designs and manufactures the ZAP-X radiosurgery platform, which is utilized for treating brain tumors and various conditions affecting the head and neck. This innovative system features a self-shielded design that eliminates the necessity for traditional radiation vaults, allowing for greater accessibility and point-of-care delivery in settings such as physician offices, ambulatory surgery centers, and satellite facilities. By enabling neurosurgeons and radiation oncologists to utilize precision radiation more effectively, Zap Surgical Systems aims to enhance treatment options for patients requiring advanced surgical interventions.

Meditrina, Inc. is a medical device company based in San Jose, California, specializing in tissue removal solutions for intrauterine pathology. Founded in 2016, the company has developed the Aveta System, an all-in-one solution designed for hysteroscopic diagnostic and therapeutic procedures. This system enables healthcare professionals to perform tasks such as the removal of polyps and fibroids in both office and operating room settings. The Aveta System features wide-angle HD hysteroscopy with electronic image-lock, advanced fluid management for better pressure and fluid control, and a compact design that allows for seamless integration into various medical environments. By providing advanced, convenient, and cost-effective options, Meditrina aims to enhance the care experience for both patients and physicians.

Lucira Health, Inc. is a medical technology company based in Emeryville, California, that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013, the company focuses on creating accessible and user-friendly testing solutions, including a disposable COVID-19 test kit designed for home use. This kit provides centralized-laboratory-accurate molecular testing in a compact format that operates on two AA batteries. It connects consumers to treatment options through a mobile application and offers a dual testing capability to determine whether viral respiratory symptoms are caused by COVID-19 or influenza. Lucira Health aims to enhance the accessibility and efficiency of infectious disease diagnostics.

Corinth MedTech, Inc. is a medical device company based in Cupertino, California, specializing in the manufacture of disposable bipolar transurethral and transcervical resectoscopes. Founded in 2011, the company has developed systems for endoscopically controlled tissue removal for male patients with benign prostatic hyperplasia (BPH) and for female patients with conditions such as abnormal uterine bleeding, fibroids, and polyps requiring hysteroscopic intervention. Corinth MedTech's proprietary technology enables medical professionals to perform precise resection and coagulation of prostate adenomas and bladder tumors, facilitating effective treatment under continuous flow conditions. The company aims to enhance patient outcomes through its innovative medical solutions.

Apostle, Inc. is a biotechnology company based in Menlo Park, California, focused on developing AI-enabled nanoDiagnostics technology for early cancer detection. Founded in 2017, the company specializes in liquid biopsy techniques, utilizing circulating free DNA (cfDNA) as a biomarker for analysis. Its innovative products include the Apostle MiniMax, a system for efficiently capturing cfDNA from blood samples, the Apostle MagTouch, which automates nucleic acid isolation, and the Apostle MiniEnrich, a technology for high-resolution DNA size enrichment. In response to the COVID-19 pandemic, Apostle introduced the Apostle COVID-19 Viral RNA Isolation System, contributing to public health efforts and serving over 13 million individuals. Apostle Diagnostics, a clinical laboratory branch of the company, is CLIA certified and California State licensed, providing accurate clinical testing services and having served over 30,000 people. Through its advancements in bioinformatics and nanotechnology, Apostle aims to enhance the diagnosis and treatment of various diseases, particularly cancer.

Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

Lucira Health, Inc. is a medical technology company based in Emeryville, California, that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013, the company focuses on creating accessible and user-friendly testing solutions, including a disposable COVID-19 test kit designed for home use. This kit provides centralized-laboratory-accurate molecular testing in a compact format that operates on two AA batteries. It connects consumers to treatment options through a mobile application and offers a dual testing capability to determine whether viral respiratory symptoms are caused by COVID-19 or influenza. Lucira Health aims to enhance the accessibility and efficiency of infectious disease diagnostics.

Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company specializes in the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights offers an integrated platform that includes proprietary consumables such as OptoSelect chips and reagent kits, along with automation systems and application software. Utilizing innovative micro-droplet technology, the company transforms biological processes, enabling researchers to study cell interactions more effectively. This platform supports various applications, including biotherapeutic discovery and development, cellular therapy manufacturing, and synthetic biology, addressing the growing demands in these fields.

NeuroVasc Technologies, Inc. is a medical device company focused on developing catheter-based technologies for treating neurovascular diseases, particularly in the context of stroke management. Established in 2015 and headquartered in Laguna Hills, California, the company has developed the Versi system, a mechanical thrombectomy device designed to remove blood clots that cause strokes. This innovative system features a flow protector and a retriever that can be delivered through a microcatheter, allowing for the regulation of blood flow during the clot retrieval process without the need for a balloon guide catheter. NeuroVasc Technologies aims to enhance treatment options for patients suffering from acute ischemic strokes by providing tools that facilitate effective intervention for healthcare professionals.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

Emboline, Inc. is a medical device company specializing in the development of cardiovascular embolic protection devices for various cardiac procedures. The company has created innovative technologies such as the Emboline Complete Accessible Protection and the Emboliner catheter, which are designed to protect the arterial bed and cerebral arteries, respectively. These devices are particularly useful during percutaneous heart valve repair and replacement procedures, as they mitigate the risk of embolic events that can impact critical organs. Founded in 2011 and headquartered in Santa Cruz, California, Emboline serves diverse markets, including cardiac surgery, cardiopulmonary bypass, interventional cardiology, and interventional electrophysiology. As of early 2013, Emboline operates as a subsidiary of CardioLogical Solutions.

Zenflow, Inc. is a medical device company based in San Francisco, California, that specializes in providing innovative solutions for men suffering from benign prostatic hyperplasia (BPH) symptoms. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, the company aims to address the significant unmet clinical need for effective urinary obstruction treatments. Zenflow's primary product is a spring-like device designed to gently prop open the urethra, restoring its normal function without damaging surrounding tissues. This approach prioritizes patient comfort and minimizes invasiveness, offering a less painful alternative to traditional treatments for urinary obstruction caused by an enlarged prostate.

Ceribell, Inc. is a medical technology company that designs and manufactures devices for electroencephalography (EEG) data acquisition and interpretation, aimed at improving the diagnosis and management of neurological conditions. Its flagship product, the Ceribell EEG System, includes a flexible EEG Headband that accommodates various hair types and head sizes, alongside a portable EEG Recorder that ensures clinical-quality data and on-device display. The system is designed to be set up by any healthcare provider within six minutes, making EEG testing more accessible and efficient. Notably, it features a unique function that converts brainwaves into sound, allowing for quicker detection of seizures without the need for specialized technicians. This innovation facilitates earlier diagnosis and targeted treatment for patients, particularly for non-convulsive seizures, thereby reducing the risk of complications and improving overall patient outcomes. Established in 2014 and based in Mountain View, California, Ceribell is committed to enhancing care in hospital ICUs, inpatient units, and emergency departments.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.